[Selective treatment of leukemia L1210 with combination of deoxycytidine and lethal doses of cytosine arabinoside].
Oral administration of deoxycytidine simultaneously with intraperitoneal injections of toxic doses of cytosine arabinosidetomice with advanced L1210 leukemia diminished the toxic effects preventing drug death of these mice. They developed a marked antitumor effect. The mean survival time of these mice was considerably extended as compared to that of untreated animals or those given one of these drugs alone. At the optimum schedule of treatment about 23% of the mice survived over 60 days. Deoxycytidine protection reduced the antileukemic effect of cytosine arabinoside administered in nontoxic doses. The deoxycytidine plus cytosine arabinose combination was ineffective in the treatment of transplantable myeloid leukemia in mice.
D000284:Administration, Oral; D000818:Animals; D003561:Cytarabine / Q000008:administration & dosage* / Q000627:therapeutic use; D003841:Deoxycytidine / Q000008:administration & dosage* / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D007274:Injections, Intraperitoneal; D007939:Leukemia L1210 / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D051379:Mice
D003561:Cytarabine; D003841:Deoxycytidine
Selektivnaia terapiia leĭkemii L1210 kombinatsieĭ dezoksitsitidina i letal'nykh doz tsitozin-arabinozida.